Clinical trials: Cerebral Palsy, Dyskinetic
Cerebral Palsy, Gait Disorders
The Effects of Exoskeletal Robot-Assisted Gait Training on Children With Cerebral Palsy: A Pilot Study
Cerebral Palsy (CP) is a complex neurodevelopmental disorder caused by early brain injury, leading to motor impairments such as muscle weakness, stiffness, and gait instability, which impact daily functioning.
- Conditions
- Cerebral Palsy, Gait Disorders, Gait Disorders in Children, Gait Disorders, Neurologic
- Trial name
- NCT05759182
- Testing
- Powered Exoskeleton Gait Training
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- COSMO ROBOTICS CO., Ltd
Cerebral Palsy, Dyskinetic
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
CP (cerebral palsy) refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination.
- Trial name
- RECLAIM-DCP (NCT03813238)
- Testing
- TEV-50717
- Where
- 70 sites in United States, Belgium and 10 more
- Volunteers
- 63 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cerebral Palsy, Dyskinetic
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Study TV50717-CNS-30081 is a 55-week study in which participants who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.
- Trial name
- NCT04200352
- Testing
- TEV-50717
- Where
- 30 sites in United States, Denmark and 7 more
- Volunteers
- 44 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Dyskinesia, Cerebral Palsy
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
The primary objective of this study is to evaluate the efficacy of valbenazine versus placebo on improving chorea in pediatric and adult participants who have dyskinesia due to cerebral palsy (DCP) with choreiform movements.
- Trial name
- NCT05206513
- Testing
- Valbenazine
- Where
- 38 sites in United States, Argentina and 8 more
- Volunteers
- 86 people
- Sponsor
- Neurocrine Biosciences